Patents by Inventor Mark A. Findeis
Mark A. Findeis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130059804Abstract: As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: August 3, 2012Publication date: March 7, 2013Applicant: SATORI PHARMACEUTICALS, INC.Inventor: Mark A. Findeis
-
Publication number: 20120329720Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: ApplicationFiled: June 29, 2012Publication date: December 27, 2012Applicant: YALE UNIVERSITYInventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
-
Publication number: 20120283217Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: July 16, 2012Publication date: November 8, 2012Applicant: SATORI PHARMACEUTICALS, INC.Inventors: Mark A. Findeis, Steffen P. Creaser
-
Patent number: 8263755Abstract: As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: GrantFiled: November 20, 2007Date of Patent: September 11, 2012Assignee: Satori Pharmaceuticals, Inc.Inventor: Mark A. Findeis
-
Patent number: 8242240Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: GrantFiled: August 27, 2010Date of Patent: August 14, 2012Assignee: Yale UniversityInventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
-
Publication number: 20110251379Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: March 3, 2011Publication date: October 13, 2011Applicant: Satori Pharmaceuticals, Inc.Inventors: Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Mark A. Findeis, Nathan Oliver Fuller, Jed Lee Hubbs, Jeffrey Lee Ives, Ruichao Shen
-
Publication number: 20110136749Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: December 1, 2010Publication date: June 9, 2011Applicant: SATORI PHARMACEUTICALS, INC.Inventors: Mark A. Findeis, Kollol Pal, Frank Schroeder
-
Publication number: 20110136750Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: December 1, 2010Publication date: June 9, 2011Applicant: SATORI PHARMACEUTICALS, INC.Inventors: Mark A. Findeis, Kollol Pal, Frank Schroeder
-
Publication number: 20110071092Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: ApplicationFiled: August 27, 2010Publication date: March 24, 2011Applicant: YALE UNIVERSITYInventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
-
Publication number: 20110009343Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: ApplicationFiled: December 21, 2009Publication date: January 13, 2011Applicant: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed
-
Patent number: 7851641Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: GrantFiled: May 16, 2006Date of Patent: December 14, 2010Assignee: Satori Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Kollol Pal, Frank Schroeder
-
Patent number: 7812118Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: GrantFiled: April 9, 2009Date of Patent: October 12, 2010Assignee: Yale UniversityInventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
-
Patent number: 7803774Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.Type: GrantFiled: November 15, 2004Date of Patent: September 28, 2010Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Kathryn Phillips, Gary L. Olsen, Christopher Self
-
Publication number: 20100197615Abstract: As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: November 20, 2007Publication date: August 5, 2010Applicant: SATORI PHARMACEUTICALS, INC.Inventor: Mark Findeis
-
Publication number: 20100144689Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: December 17, 2009Publication date: June 10, 2010Applicant: Satori Pharmaceuticals, Inc.Inventor: Mark A. FINDEIS
-
Publication number: 20100056487Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.Type: ApplicationFiled: November 20, 2007Publication date: March 4, 2010Applicant: Satori Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Steffen P. Creaser
-
Patent number: 7658917Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: June 17, 2003Date of Patent: February 9, 2010Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Ethan R. Signer, James Wakefield, Laura Kasman, Gary Musso, Michael J. Reed
-
Publication number: 20090286748Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: ApplicationFiled: April 9, 2009Publication date: November 19, 2009Applicant: Yale UniversityInventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
-
Patent number: 7534858Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: GrantFiled: May 22, 2006Date of Patent: May 19, 2009Assignee: Yale UniversityInventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
-
Publication number: 20080032896Abstract: Methods for identifying a compound that binds to a target are described. In general, the methods involve forming a first library comprising a multiplicity of peptides, identifying one or more peptides that bind to the target and determining a peptide motif therefrom, forming a second library comprising a multiplicity of compounds designed based on the peptide motif, selecting from the second library at least one compound that binds to the target, and determining the structure or structures of the at least one compound that binds to the target. Libraries of compounds based on a peptide motif and compounds identified by the methods of the invention are also disclosed.Type: ApplicationFiled: February 9, 2007Publication date: February 7, 2008Inventors: Howard Benjamin, Mark Findeis, Malcolm Gefter, Gary Musso, Ethan Signer